THAR

2.37

9.22% 0.20

Handel nachbörslich: 2.28 -0.09 -3.80%

Tharimmune Inc (THAR)

Überblick Nachrichten Preisverlauf Financials Warum fällt THAR? Forum Prognose

Schlusskurs vom Vortag:

$2.17

Offen:

$2.31

24-Stunden-Volumen:

8.76M

Relative Volume:

7.64

Marktkapitalisierung:

$2.99M

Einnahmen:

Nettoeinkommen (Verlust:

$-9.32M

KGV:

-3.2917

EPS:

-0.72

Netto-Cashflow:

$-7.30M

1W Leistung:

+4.87%

1M Leistung:

+8.22%

6M Leistung:

-56.23%

1J Leistung:

-24.76%

1-Tages-Spanne:

$1.85

$2.42

1-Wochen-Bereich:

$1.85

$2.42

52-Wochen-Spanne:

$1.835

$71.85

Tharimmune Inc Stock (THAR) Company Profile

Firmenname

Tharimmune Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

302-743-2995

Adresse

1200 ROUTE 22 EAST, BRIDGEWATER

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-08-05

Neueste SEC-Einreichungen

THAR's Discussions on Twitter

Vergleichen Sie THAR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
THAR	2.37	2.99M	0	-9.32M	-7.30M	-0.72
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Tharimmune Inc Aktie (THAR) Neueste Nachrichten

11:47 AM

What's Going On With Tharimmune Shares Monday? - Benzinga

11:47 AM

08:12 AM

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Brazosport Facts

08:12 AM

08:00 AM

Tharimmune's Liver Drug Shows 33% Itch Reduction in Phase 1 Trial, Phase 2 Planned | THAR Stock News - StockTitan

08:00 AM

Nov 14, 2024

Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock - Investing.com India

Nov 14, 2024

Nov 13, 2024

Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock By Investing.com - Investing.com Canada

Nov 13, 2024

What's Going On With Tharimmune Shares Wednesday? - MSN

Nov 13, 2024

Tharimmune set to receive European patent for cancer therapy tech - Investing.com

Nov 13, 2024

Tharimmune set to receive European patent for cancer therapy tech By Investing.com - Investing.com UK

Nov 13, 2024

Tharimmune Secures Key European Patent for Revolutionary Nanoparticle Drug Delivery System | THAR Stock News - StockTitan

Nov 13, 2024

Nov 04, 2024

Tharimmune Announces Upcoming Conference Presentations - StockTitan

Nov 04, 2024

Nov 01, 2024

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN

Nov 01, 2024

Oct 31, 2024

Dow Surges Over 150 Points; Alphabet Posts Upbeat Results - MSN

Oct 31, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN

Oct 31, 2024

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN

Oct 31, 2024

Oct 30, 2024

S&P 500 Edges Lower; US Crude Oil Inventories Fall - MSN

Oct 30, 2024

New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following "Positive Feedback" - MSN

Oct 30, 2024

Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga

Oct 30, 2024

S&P 500 Total Return (TCU24) Quote - The Globe and Mail

Oct 30, 2024

Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Coversee more stocks inside... - openPR

Oct 30, 2024

Tharimmune (THAR) Stock Rallies After Positive EMA Feedback Boosts Confidence - Stocks Telegraph

Oct 30, 2024

Tharimmune receives regulatory feedback from EMA for TH104 program - TipRanks

Oct 30, 2024

Tharimmune secures EMA feedback on pruritus drug trial - Investing.com

Oct 30, 2024

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - StockTitan

Oct 30, 2024